Trials / Completed
CompletedNCT05537571
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Silence Therapeutics plc · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SLN360 | SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA) |
| DRUG | Placebo | Sodium chloride, solution for injection |
Timeline
- Start date
- 2022-12-13
- Primary completion
- 2024-01-11
- Completion
- 2024-07-01
- First posted
- 2022-09-13
- Last updated
- 2025-07-01
- Results posted
- 2025-07-01
Locations
29 sites across 7 countries: Australia, Czechia, Denmark, Netherlands, Slovakia, South Africa, United Kingdom
Source: ClinicalTrials.gov record NCT05537571. Inclusion in this directory is not an endorsement.